sitagliptin phosphate
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus Non-insulin-dependent
Conditions
Diabetes Mellitus Non-insulin-dependent
Trial Timeline
Mar 1, 2008 → Mar 1, 2008
NCT ID
NCT00642798About sitagliptin phosphate
sitagliptin phosphate is a phase 1 stage product being developed by Merck for Diabetes Mellitus Non-insulin-dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00642798. Target conditions include Diabetes Mellitus Non-insulin-dependent.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01512797 | Pre-clinical | Completed |
| NCT00833027 | Approved | Completed |
| NCT00642798 | Phase 1 | Completed |
| NCT00545584 | Phase 3 | Completed |
| NCT00832390 | Approved | Completed |
| NCT00696826 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus Non-insulin-dependent